Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
625 stopped studies mapped to Malignant Urinary System Neoplasm and descendants · 88% state a reason
Over the 625 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01727336 | Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma | Phase 2 | terminated | Nov 16, 2012 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | The study was terminated by the sponsor following unblinding of the Progression Free Survival… | Other (stated, no rule matched) |
| NCT04127318 | Low-moderate Intensity Pedaling During Immunotherapy Administration | N/A | withdrawn | Oct 15, 2019 | Rush University Medical Center | lack of resources | Other (stated, no rule matched) |
| NCT05395260 | FL- 101 Study in Non-Metastatic MIBC | Early Phase 1 | withdrawn | May 27, 2022 | Flame Biosciences | Sponsor Decision | Sponsor / business decision |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT01582009 | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal… | Phase 1 / Phase 2 | terminated | Apr 20, 2012 | Roswell Park Cancer Institute | pts off study, PI left institute | Investigator |
| NCT01769885 | Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer | N/A | withdrawn | Jan 17, 2013 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT02735512 | MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples… | — | terminated | Apr 12, 2016 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT04972253 | Phase I BLASST-3 Trial((BLASST)-3) | Phase 1 | withdrawn | Jul 22, 2021 | Guru P. Sonpavde | Low Accrual | Enrollment / accrual |
| NCT02781506 | Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell… | Phase 2 | terminated | May 24, 2016 | University of Texas Southwestern Medical Center | Since the treatment landscape for metastatic kidney cancer changed, patients were not becoming… | Other (stated, no rule matched) |
| NCT05263609 | Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | Phase 2 | withdrawn | Mar 2, 2022 | University of Oklahoma | PI left University | Investigator |
| NCT02901548 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial… | Phase 2 | terminated | Sep 15, 2016 | H. Lee Moffitt Cancer Center and Research Institute | Study closed early due to futility | Efficacy / futility |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT01732107 | Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression | Phase 2 | terminated | Nov 22, 2012 | Noah Hahn, M.D. | Development of dovitinib was stopped. | Other (stated, no rule matched) |
| NCT03050060 | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab,… | Phase 2 | terminated | Feb 10, 2017 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer… | Phase 1 | terminated | Nov 21, 2019 | Augusta University | Closed by IRB on 3/28/22 | Other (stated, no rule matched) |
| NCT04961320 | Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell… | N/A | withdrawn | Jul 14, 2021 | City of Hope Medical Center | slow accrual | Enrollment / accrual |
| NCT04150562 | Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma | Phase 2 | terminated | Nov 4, 2019 | National Cancer Institute (NCI) | This study was terminated early due to manufacturer withdrawal of support (study medication) due to… | Drug supply |
| NCT03839472 | Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors | N/A | withdrawn | Feb 15, 2019 | Case Comprehensive Cancer Center | Revision to improve cell recovery | Other (stated, no rule matched) |
| NCT05104905 | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and…(RENACOL) | Phase 1 / Phase 2 | withdrawn | Nov 3, 2021 | Faron Pharmaceuticals Ltd | Since no patients have been enrolled in RENACOL, and safety and tolerability data is rapidly… | Safety / toxicity |
| NCT03718741 | Prospective Study of Adjuvant Radiotherapy in High Risk Bladder Cancer.(Bladder-Aid) | N/A | terminated | Oct 24, 2018 | Istituto Clinico Humanitas | few patients enrolled | Enrollment / accrual |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC… | Phase 1 / Phase 2 | terminated | Aug 31, 2018 | Apollomics (Australia) Pty. Ltd. | Study terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT02164942 | LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer | — | terminated | Jun 17, 2014 | Wake Forest University Health Sciences | Futility | Efficacy / futility |
| NCT03266900 | A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma…(RESECT) | Early Phase 1 | terminated | Aug 30, 2017 | University Health Network, Toronto | Difficulties with accrual | Enrollment / accrual |
| NCT05260788 | Mapping 3D Bladder | — | withdrawn | Mar 2, 2022 | University Health Network, Toronto | Administrative issues. | Other (stated, no rule matched) |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT02061605 | First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial…(LTW-KIDNEY) | N/A | withdrawn | Feb 13, 2014 | Laser Tissue Welding, Inc. | not stated | Not stated |
| NCT03334409 | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney… | Phase 2 | terminated | Nov 7, 2017 | Academic and Community Cancer Research United | Due to loss of funding from the private foundation source | Funding |
| NCT04960956 | Glycosylation of Exosomes in Prostate and Urothelial Carcinoma | — | terminated | Jul 14, 2021 | Indiana University | Could not identify a replacement Principal Investigator. | Investigator |
| NCT03138538 | M8891 First in Human in Solid Tumors(M8891) | Phase 1 | terminated | May 3, 2017 | EMD Serono Research & Development Institute, Inc. | As part of a portfolio-level management of the company's oncology pipeline, it was decided to stop… | Sponsor / business decision |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | Phase 2 | terminated | Jun 1, 2015 | TC Biopharm | not stated | Not stated |
| NCT03549650 | Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms | Phase 2 | terminated | Jun 8, 2018 | Sir Mortimer B. Davis - Jewish General Hospital | Given the updated precautions on Elmiron as well as the risk benefit profile, we have decided to… | Other (stated, no rule matched) |
| NCT01954173 | Adjuvant Radiation for High Risk Bladder Cancer | N/A | terminated | Oct 1, 2013 | Emory University | Slow accrual | Enrollment / accrual |
| NCT01126749 | Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus… | Phase 1 / Phase 2 | terminated | May 20, 2010 | Eisai Inc. | Study was terminated as per sponsor's decision | Sponsor / business decision |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid… | Phase 1 / Phase 2 | terminated | Mar 14, 2019 | Calithera Biosciences, Inc | Slow Enrollment | Enrollment / accrual |
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | Phase 2 | withdrawn | Jan 30, 2017 | Guru Sonpavde | Principal investigator left lead institution and efforts to open the protocol at another… | Investigator |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT01093066 | Prospective Multicentric Evaluation of a Bladder Preservation Strategy(ReChiVe) | Phase 2 | terminated | Mar 25, 2010 | Centre Hospitalier Universitaire de Saint Etienne | Difficulties in the inclusion and follow-up of patients | Other (stated, no rule matched) |
| NCT03287050 | Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial… | Phase 2 | terminated | Sep 19, 2017 | University of Michigan Rogel Cancer Center | due to changing therapeutic landscape in metastatic bladder cancer and lack of… | Other (stated, no rule matched) |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or… | Phase 1 | terminated | May 11, 2016 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT02792192 | Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille… | Phase 1 / Phase 2 | terminated | Jun 7, 2016 | Hoffmann-La Roche | The study was terminated early as the study had met its goals of providing preliminary safety and… | Safety / toxicity |
| NCT02563561 | A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing… | Phase 3 | terminated | Sep 30, 2015 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT03408652 | Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in…(MOSCAR) | Phase 3 | terminated | Jan 24, 2018 | Centre Leon Berard | lack of recruitment | Enrollment / accrual |
| NCT04273724 | Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment… | N/A | terminated | Feb 18, 2020 | UNC Lineberger Comprehensive Cancer Center | Investigator left and research was discontinued. | Investigator |
| NCT04280640 | Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical… | — | withdrawn | Feb 21, 2020 | UNC Lineberger Comprehensive Cancer Center | PI left UNC. | Investigator |
| NCT03224182 | A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants… | Phase 3 | terminated | Jul 21, 2017 | Spectrum Pharmaceuticals, Inc | Suspended development | Other (stated, no rule matched) |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic… | Phase 2 | terminated | Apr 14, 2017 | Weill Medical College of Cornell University | Lack of accrual | Enrollment / accrual |
| NCT02885649 | Enzalutamide Before Surgery in Treating Patients With Kidney Cancer | Early Phase 1 | terminated | Aug 31, 2016 | Rutgers, The State University of New Jersey | Funding unavailable | Funding |
| NCT02959554 | Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or…(NIVOSWITCH) | Phase 2 | terminated | Nov 9, 2016 | AIO-Studien-gGmbH | not stated | Not stated |
| NCT04066595 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.(CabUC) | Phase 2 | terminated | Aug 26, 2019 | Johannes Gutenberg University Mainz | Recruitment problems | Enrollment / accrual |
| NCT04680416 | Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to… | — | withdrawn | Dec 23, 2020 | TScan Therapeutics, Inc. | Lack of patient samples | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 6, 2022source: clinicaltrials